July 02, 2025 a 08:38 pm
TECH: Analysts Ratings - Bio-Techne Corporation
Bio-Techne Corporation, known for its diverse life science reagents and diagnostic solutions, continues to attract analyst interest with a consistent rating profile. With a stable base of Strong Buy and Buy recommendations, the company demonstrates resilience amidst market fluctuations. This report provides an in-depth analysis of the latest analyst ratings and sentiment dynamics involving Bio-Techne's stock (TECH).
Historical Stock Grades
Based on the latest data, Bio-Techne Corporation has shown a consistent trend in positive ratings. The company's stock is characterized by a steady number of Buy and Strong Buy ratings:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 8 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past year, the sentiment around Bio-Techne's stock has shown stability with minor fluctuations. Analysts have maintained their strategies with reinforced Buy ratings. Key observations include:
- The total number of recommendations has remained steady in recent months.
- Persistent reinforcement in Buy ratings suggests sustained market confidence.
- A consistent count of Hold ratings, without trends towards Sell, indicates market bullishness.
Percentage Trends
A closer look into percentage trends reveals consistent stability among analyst recommendations. The distribution highlights:
- Strong Buy and Buy compose the majority of ratings, maintaining an optimistic outlook.
- Hold ratings, at approximately 25%, remain constant across the board.
- A noticeable stability in percentage distribution, with a shift from more conservative projecting lesser Strong Buys.
- Over the past year, the trend is characterized by a slight shift towards more cautious positions, indicative of strategic reassessments.
Latest Analyst Recommendations
Recent recommendations underscore a stable outlook with consistent analyst opinions:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-05 | Buy | Buy | Benchmark |
| 2025-05-09 | Buy | Buy | UBS |
| 2025-05-08 | Sector Perform | Sector Perform | RBC Capital |
| 2025-05-08 | Hold | Hold | Stifel |
| 2025-05-08 | Buy | Buy | Benchmark |
Analyst Recommendations with Change of Opinion
Recent changes signify a strategic reevaluation among analysts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-09 | Sector Weight | Overweight | Keybanc |
| 2025-04-08 | Sector Weight | Overweight | Keybanc |
| 2025-02-19 | Neutral | Outperform | Baird |
| 2024-05-22 | Neutral | Buy | Citigroup |
| 2024-02-02 | Hold | Buy | Stifel |
Interpretation
The prevailing ratings for Bio-Techne exhibit a strong market sentiment, characterized by stability and a consistent preference for Buy positions. Analysts' assessments demonstrate a cautious but optimistic stance, with a tendency to uphold existing recommendations. The data indicates no clear indication of increased uncertainty, maintaining an air of confidence around the stock. The stability in analyst opinions underscores a balanced and resilient market outlook.
Conclusion
Bio-Techne Corporation has retained its positive stance among analysts, emphasizing potential sustained growth and market stability. The corporation's firm grasp in life sciences and diagnostics markets continues to drive confidence among investors. While subtle shifts suggest a reassessment of past bullishness, the outlook remains generally positive with minimal downside risk anticipated. Monitoring future trends and analyst sentiment will be key to evaluating long-term potential.